RWA Wealth Partners LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

RWA Wealth Partners LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 198.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 291,324 shares of the biopharmaceutical company’s stock after buying an additional 193,726 shares during the period. RWA Wealth Partners LLC’s holdings in Pfizer were worth $8,387,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Investment Advisory Services Inc. TX ADV grew its stake in Pfizer by 1.6% in the 3rd quarter. Investment Advisory Services Inc. TX ADV now owns 20,097 shares of the biopharmaceutical company’s stock valued at $667,000 after buying an additional 325 shares in the last quarter. Trifecta Capital Advisors LLC grew its stake in Pfizer by 3.7% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 325 shares in the last quarter. Powers Advisory Group LLC grew its stake in Pfizer by 2.4% in the 3rd quarter. Powers Advisory Group LLC now owns 13,759 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 329 shares in the last quarter. Confluence Wealth Services Inc. grew its stake in Pfizer by 0.5% in the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after buying an additional 342 shares in the last quarter. Finally, Carr Financial Group Corp grew its stake in Pfizer by 3.3% in the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after buying an additional 355 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock opened at $26.32 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $149.04 billion, a PE ratio of 72.94, a P/E/G ratio of 1.17 and a beta of 0.61. The firm has a fifty day simple moving average of $27.08 and a two-hundred day simple moving average of $28.56. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.14 earnings per share. Research analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.